Metrics to compare | ASTR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipASTRPeersSector | |
|---|---|---|---|---|
P/E Ratio | 108.0x | 35.3x | −0.3x | |
PEG Ratio | 1.74 | 0.20 | 0.00 | |
Price/Book | 23.2x | 5.0x | 2.6x | |
Price / LTM Sales | 8.9x | 6.6x | 3.0x | |
Upside (Analyst Target) | - | 24.4% | 56.3% | |
Fair Value Upside | Unlock | 2.9% | 9.2% | Unlock |
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company has a strategic collaboration with Leica Biosystems and Daiichi Sankyo Company, Limited for the development of an immunohistochemistry assay and an image analysis algorithm for the TROP2 NMR biomarker in non-small cell lung cancer. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.